U-VRTX

Q:VRTX - VERTEX PHARMACEUTICAL - http://www.vpharm.com/

14:13:46 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
VRTX - Q	8.9	405.25	·	405.45	3.1	405.25	+5.33	1.3	381.6	154,083	11,456	404.00 406.74 403.47	448.40 316.43	13:53:03	00:45	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market: Nasdaq -- Bid Tick: Up -- UPC Restricted: No

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Options · Portfolio

Recent Trades - Last 10 of 11456

Date ET	Symbol	Type	Headline
2024-04-23 00:45	U:VRTX	News Release200	VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
2024-04-18 08:00	U:VRTX	News Release200	Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
2024-04-10 16:01	U:VRTX	News Release200	Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
2024-04-09 16:05	U:VRTX	News Release200	Vertex to Announce First Quarter 2024 Financial Results on May 6
2024-04-01 11:00	U:VRTX	News Release200	Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2024-04-01 08:00	U:VRTX	News Release200	Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease

Date ET

Symbol

Type

Headline

2024-04-23 00:45

News Release

2024-04-18 08:00

News Release